Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : UBS Adjusts Gilead Sciences' Price Target to $68 From $64, Maintains Neutral Rating

08/02/2021 | 10:26am EDT


© MT Newswires 2021
All news about GILEAD SCIENCES, INC.
10/19Atea plunges after COVID-19 treatment fails to help patients in study
RE
10/19GILEAD SCIENCES : to Donate 103,000 Vials of Veklury to Indonesia, Armenia
MT
10/19GILEAD SCIENCES : Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis..
BU
10/19GILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
AQ
10/18GILEAD SCIENCES : Secures FDA Approval for Expanded Indication of Biktarvy for Treatment o..
MT
10/18GILEAD SCIENCES : U.S. Food and Drug Administration Approves Expanded Indication of Gilead..
BU
10/18Gilead Says FDA Approves Expanded Indication of Biktarvy for Treatment of HIV-1 in Pedi..
DJ
10/15GILEAD SCIENCES : Says Breast Cancer Therapy Receives Positive Opinion by European Medicin..
MT
10/15GILEAD SCIENCES : Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for..
BU
10/15Gilead's Sacituzumab Govitecan Gets Positive CHMP Opinion in Breast Cancer
DJ
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 25 182 M - -
Net income 2021 6 628 M - -
Net Debt 2021 23 041 M - -
P/E ratio 2021 13,2x
Yield 2021 4,22%
Capitalization 83 880 M 83 880 M -
EV / Sales 2021 4,25x
EV / Sales 2022 4,19x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 66,90 $
Average target price 76,35 $
Spread / Average Target 14,1%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.14.83%83 880
WUXI APPTEC CO., LTD.29.16%65 873
BIONTECH SE222.44%63 059
REGENERON PHARMACEUTICALS14.28%56 504
VERTEX PHARMACEUTICALS-21.55%46 905
BEIGENE, LTD.45.52%33 674